Arcus Biosciences, Inc. (NYSE:RCUS) Q4 2023 Earnings Conference Call February 21, 2024 5:00 PM ET

Company Participants

Pia Eaves – Vice President of Investor Relations

Terry Rosen – CEO

Jennifer Jarrett – COO

Dimitry Nuyten – CMO

Bob Goeltz – CFO

Juan Jaen – President

Conference Call Participants

Terence Flynn – Morgan Stanley

Peter Lawson – Barclays

Kaveri Pohlman – BTIG

Jonathan Miller – Evercore ISI

Yigal Nochomovitz – Citigroup

Robyn Karnauskas – Truist

Daina Graybosch – Leerink Partners


Hello and welcome to the Arcus Biosciences Full Year/Q4 2023 Earnings Call. My name is Elliot, and I’ll be coordinating your call today. [Operator Instructions].

I’d now like to hand over to Pia Eaves, Vice President of Investor Relations. The floor is yours. Please go ahead.

Pia Eaves

Hello, everyone and thank you for joining us on today’s conference call to discuss Arcus’s fourth quarter 2023 financial results and pipeline updates. I’d like to remind you that on this call, management will make forward-looking statements, including statements about our cash runway and our expected clinical development milestones and timelines.

All statements other than historical facts reflect the current beliefs and expectations of management and involve risks and uncertainties that may cause our actual results to differ from those expressed. Those risks and uncertainties are described in our annual report on Form 10-K, which has been filed with the SEC. We strongly encourage you to review our filings.

Today you’ll hear from our CEO, Terry Rosen; COO, Jennifer Jarrett; CMO, Dimitry Nuyten; and CFO, Bob Goeltz. We’ll also be joined by our President, Juan Jaen, for questions after the prepared remarks. During today’s call, we’ll refer to slides in our corporate deck, which can be found on the Investors section of our website.

With that, I’ll now turn it over to Terry.

Source link